Online inquiry

IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4899MR)

This product GTTS-WQ4899MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets ACVR2 gene. The antibody can be applied in Cachexia, Type 2 diabetes, Sarcopenia research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001278579.2; NM_001106.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 92; 93
UniProt ID P27037; Q13705
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ4899MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6488MR IVTScrip™ mRNA-Anti-S, CT-P-59(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CT-P-59
GTTS-WQ4151MR IVTScrip™ mRNA-Anti-PDCD1, BI-754091(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BI-754091
GTTS-WQ9832MR IVTScrip™ mRNA-Anti-ICOS, JTX-2011(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA JTX-2011
GTTS-WQ8507MR IVTScrip™ mRNA-Anti-B4GALNT1, Hu3F8(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Hu3F8
GTTS-WQ9581MR IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA JNJ-61186372
GTTS-WQ1112MR IVTScrip™ mRNA-Anti-MAPT, ABBV-8E12(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABBV-8E12
GTTS-WQ4104MR IVTScrip™ mRNA-Anti-oxLDL, BI-204(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BI-204
GTTS-WQ11861MR IVTScrip™ mRNA-Anti-TIGIT, MK-7684(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MK-7684
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW